MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (COPD-Chronic Obstructive Pulmonary Disorder), Emphysema
Verona Pharma plc (NASDAQ: VRNA)*
Organization & Developments: Verona Pharma
Parents
Verona Pharma plc (NASDAQ: VRNA)*
Children
*It is developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD)
*Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs.
2020: Verona Pharma up 59% premarket on positive ensifentrine data_seekingalpha.com
2021: Revisiting Verona Pharmaceuticals
2022: Biotech Analysis Central Preview Series: Verona Pharma_ seekingalpha.com
2022: Phase 3 ENHANCE-2 trial of nebulized ensifentrine to treat chronic obstructive pulmonary disease (COPD) met its primary endpoint and secondary endpoints.
2022: Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data biospace
2022: Verona Pharma: An Updated Investment Thesis_ seekingalpha.com
2022: Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point_seekingalpha.com
2023: Verona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled Drug (NASDAQ:VRNA)
2023: Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment_seekingalpha.com
2024: US FDA approves Verona Pharma's inhaled COPD therapy
2024: Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
2024: Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation
2024: Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability
2024: Verona Pharma: A Few Points From The Bull And Bear Case
2024: Verona Pharma: In COPD, There's A Corner With Their Name On It
2024: Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
2024: Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
2025: Verona Pharma: A Blockbuster Franchise In The Making
2025: Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Jumps
Finance & Acquisitions: Verona Pharma
Key People: Verona Pharma